Armata enters 35M credit agreement with Innoviva
| ARMP Stock | USD 2.20 0.01 0.45% |
Slightly above 61% of Armata Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Armata Pharmaceuticals suggests that many traders are alarmed. Armata Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Armata Pharmaceuticals. Many technical investors use Armata Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Armata |
Armata Pharmaceuticals secures 35M credit agreement with Innovivas subsidiary to advance lead therapeutic phage candidates for infections caused by...
Read at seekingalpha.com
 |
Armata Pharmaceuticals Fundamental Analysis
We analyze Armata Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Armata Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Armata Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Armata Pharmaceuticals is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Armata Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Armata Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Armata Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Armata Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Armata Pharmaceuticals Related Equities
| PHGE | Biomx | 1.56 | ||||
| ANIX | Anixa Biosciences | 2.00 |
Additional Tools for Armata Stock Analysis
When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.